This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype., Clinical Cancer Research, August 2020, American Association for Cancer Research (AACR),
DOI: 10.1158/1078-0432.ccr-20-1731.
You can read the full text:
The following have contributed to this page
